Zymeworks (ZYME) Financials

$12.43 +0.61 (+5.16%)

Closing price 05/20/2025 04:00 PM Eastern

Extended Trading

$12.33 -0.10 (-0.80%)

As of 08:37 AM Eastern

Annual Income Statements for Zymeworks

This table shows Zymeworks' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022	2021	2020
Period end date	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020
Net Income / (Loss) Attributable to Common Shareholders	-123	-119	124	-212	-181
Consolidated Net Income / (Loss)	-123	-119	124	-212	-181
Net Income / (Loss) Continuing Operations	-123	-119	124	-212	-181
Total Pre-Tax Income	-117	-119	135	-212	-180
Total Operating Income	-137	-138	131	-216	-187
Total Gross Profit	76	76	412	27	39
Total Revenue	76	76	412	27	39
Operating Revenue	76	76	412	27	39
Total Cost of Revenue	0.00	0.00	0.00	0.00	0.00
Total Operating Expenses	213	214	282	242	226
Selling, General & Admin Expense	62	70	73	43	55
Research & Development Expense	135	144	209	200	171
Impairment Charge	17	0.00	0.00	-	-
Total Other Income / (Expense), net	20	19	4.71	3.27	7.35
Interest & Investment Income	20	20	3.60	1.97	5.70
Other Income / (Expense), net	0.56	-0.89	1.11	1.31	1.65
Income Tax Expense	6.08	-0.57	11	-0.52	0.43
Basic Earnings per Share	($1.62)	($1.72)	$1.91	($4.11)	($3.58)
Weighted Average Basic Shares Outstanding	75.85M	68.86M	65.19M	51.55M	50.38M
Diluted Earnings per Share	($1.62)	($1.72)	$1.90	($4.61)	($3.58)
Weighted Average Diluted Shares Outstanding	75.88M	68.86M	65.25M	52.13M	50.38M
Weighted Average Basic & Diluted Shares Outstanding	69.58M	70.57M	64.04M	-	-

This table shows Zymeworks' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Period end date	3/31/2025	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022
Net Income / (Loss) Attributable to Common Shareholders	-22	-24	-28	-38	-33	-13	-29	-53	-24	309	-48
Consolidated Net Income / (Loss)	-23	-24	-30	-38	-32	-14	-29	-51	-24	309	-48
Net Income / (Loss) Continuing Operations	-23	-24	-30	-38	-32	-14	-29	-51	-24	309	-48
Total Pre-Tax Income	-22	-18	-30	-38	-32	-19	-28	-49	-23	320	-48
Total Operating Income	-26	-22	-34	-43	-38	-23	-33	-54	-27	319	-50
Total Gross Profit	27	31	16	19	10	17	17	7.00	36	402	2.63
Total Revenue	27	31	16	19	10	17	17	7.00	36	402	2.63
Operating Revenue	27	31	16	19	10	17	17	7.00	36	402	2.63
Total Cost of Revenue	0.00	-	0.00	0.00	0.00	-	0.00	0.00	0.00	-	0.00
Total Operating Expenses	53	53	50	62	48	40	50	61	63	83	53
Selling, General & Admin Expense	17	16	14	16	16	15	17	22	17	30	16
Research & Development Expense	36	20	36	46	32	26	33	39	46	53	37
Total Other Income / (Expense), net	3.47	4.43	4.58	5.27	6.22	4.22	5.66	4.62	4.32	1.04	2.48
Interest & Investment Income	3.42	4.08	4.79	5.15	5.92	5.05	5.03	4.83	4.81	1.73	1.13
Other Income / (Expense), net	0.05	0.34	-0.20	0.11	0.30	-0.83	0.63	-0.21	-0.49	-0.69	1.36
Income Tax Expense	0.50	5.72	0.23	0.07	0.08	-4.72	1.11	1.65	1.39	11	-0.03
Other Adjustments to Net Income / (Loss) Attributable to Common Shareholders)	-0.55	-	-1.91	0.18	1.12	-	0.49	1.87	-0.72	-	0.00
Basic Earnings per Share	($0.30)	($0.32)	($0.39)	($0.49)	($0.42)	($0.19)	($0.41)	($0.76)	($0.36)	$4.78	($0.72)
Weighted Average Basic Shares Outstanding	75.17M	75.85M	76.13M	76.39M	76.21M	68.86M	70.58M	67.28M	66.74M	65.19M	66.48M
Diluted Earnings per Share	($0.30)	($0.32)	($0.39)	($0.49)	($0.42)	($0.18)	($0.41)	($0.76)	($0.37)	$4.78	($0.72)
Weighted Average Diluted Shares Outstanding	75.23M	75.88M	76.16M	76.40M	76.25M	68.86M	70.58M	67.28M	66.74M	65.25M	66.48M
Weighted Average Basic & Diluted Shares Outstanding	69.68M	69.58M	68.88M	71.05M	70.70M	70.57M	70.00M	67.83M	64.17M	64.04M	-

This table details how cash moves in and out of Zymeworks' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022	2021	2020
Period end date	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020
Net Change in Cash & Equivalents	-91	-243	199	-40	114
Net Cash From Operating Activities	-110	-118	144	-192	-151
Net Cash From Continuing Operating Activities	-110	-118	144	-192	-151
Net Income / (Loss) Continuing Operations	-123	-119	124	-212	-181
Consolidated Net Income / (Loss)	-123	-119	124	-212	-181
Depreciation Expense	4.19	7.46	6.22	3.74	3.36
Amortization Expense	7.01	9.84	5.78	5.84	6.92
Non-Cash Adjustments To Reconcile Net Income	34	8.74	2.06	10	29
Changes in Operating Assets and Liabilities, net	-32	-26	5.71	-0.35	-9.58
Net Cash From Investing Activities	39	-207	-54	145	-43
Net Cash From Continuing Investing Activities	39	-207	-54	145	-43
Purchase of Property, Plant & Equipment	-1.99	-2.47	-8.15	-12	-4.31
Acquisitions	-1.08	-1.60	-4.98	-0.88	-1.96
Purchase of Investments	-284	-553	-113	-35	-37
Sale and/or Maturity of Investments	326	350	72	193	-
Net Cash From Financing Activities	-20	82	109	8.01	309
Net Cash From Continuing Financing Activities	-20	82	109	8.01	308
Repurchase of Common Equity	-30	0.00	0.00	-	-
Issuance of Common Equity	9.79	82	109	8.50	308
Other Financing Activities, net	-0.19	-0.07	-0.61	-0.49	-0.04
Effect of Exchange Rate Changes	0.29	0.35	0.20	-0.33	-0.55
Cash Income Taxes Paid	3.18	0.17	10	-	-

This table details how cash moves in and out of Zymeworks' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Period end date	3/31/2025	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022
Net Change in Cash & Equivalents	10	-56	51	-44	-43	63	-48	-39	-219	305	-103
Net Cash From Operating Activities	-3.41	-42	-5.88	-25	-38	14	-43	-6.40	-83	327	-73
Net Cash From Continuing Operating Activities	-3.41	-42	-5.88	-25	-38	14	-43	-6.40	-83	327	-73
Net Income / (Loss) Continuing Operations	-23	-24	-30	-38	-32	-14	-29	-51	-24	309	-48
Consolidated Net Income / (Loss)	-23	-24	-30	-38	-32	-14	-29	-51	-24	309	-48
Depreciation Expense	0.98	1.00	1.04	1.10	1.06	1.54	2.40	1.94	1.58	1.15	1.39
Amortization Expense	2.32	2.69	1.63	1.43	1.25	1.81	4.14	2.58	1.32	1.16	0.81
Non-Cash Adjustments To Reconcile Net Income	6.37	4.13	4.80	22	3.07	4.39	1.52	0.80	2.03	4.80	2.98
Changes in Operating Assets and Liabilities, net	9.55	-26	17	-11	-11	21	-22	39	-64	11	-30
Net Cash From Investing Activities	12	-6.21	72	-20	-7.32	-1.34	-7.02	-61	-138	-22	-30
Net Cash From Continuing Investing Activities	12	-6.21	72	-20	-7.32	-1.34	-7.02	-61	-138	-22	-30
Purchase of Property, Plant & Equipment	-0.02	-0.31	-0.90	-0.59	-0.19	-0.36	-0.93	-0.80	-0.39	-0.35	-0.98
Acquisitions	-0.32	-	-0.10	-0.50	-0.47	-1.40	-0.21	-	0.00	-0.54	-2.81
Purchase of Investments	-34	-54	-53	-111	-67	-62	-125	-184	-182	25	-70
Sale and/or Maturity of Investments	47	48	126	92	60	62	119	124	44	-46	43
Net Cash From Financing Activities	1.32	-8.64	-15	1.05	2.12	51	1.90	28	1.74	-0.38	0.63
Net Cash From Continuing Financing Activities	1.32	-8.64	-15	1.05	2.12	51	1.90	28	1.74	-0.38	0.63
Issuance of Common Equity	1.32	0.79	5.74	1.13	2.13	51	1.91	28	1.75	0.14	0.64
Effect of Exchange Rate Changes	0.01	0.11	-0.01	0.06	0.12	-0.00	0.02	-0.01	0.35	-0.09	0.25
Cash Income Taxes Paid	0.39	-	-	-	-	-	-	-	-	-	-

This table presents Zymeworks' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022	2021
Period end date	12/31/2024	12/31/2023	12/31/2022	12/31/2021
Total Assets	463	581	649	389
Total Current Assets	300	413	545	288
Cash & Equivalents	66	158	401	202
Short-Term Investments	160	217	91	51
Accounts Receivable	56	19	33	16
Prepaid Expenses	19	19	19	20
Plant, Property, & Equipment, net	18	20	25	23
Total Noncurrent Assets	145	148	79	78
Long-Term Investments	98	82	0.89	0.89
Goodwill	12	12	12	12
Intangible Assets	4.58	25	26	21
Noncurrent Deferred & Refundable Income Taxes	4.39	3.62	1.35	3.07
Other Noncurrent Operating Assets	26	25	39	41
Total Liabilities & Shareholders' Equity	463	581	649	389
Total Liabilities	124	116	156	140
Total Current Liabilities	88	56	96	72
Accounts Payable	60	46	87	63
Current Deferred Revenue	26	3.70	2.35	0.00
Current Deferred & Payable Income Tax Liabilities	0.13	1.81	0.84	0.00
Other Current Liabilities	2.74	4.26	4.96	9.06
Total Noncurrent Liabilities	36	60	60	68
Noncurrent Deferred Revenue	15	33	31	33
Noncurrent Deferred & Payable Income Tax Liabilities	4.76	3.30	1.79	1.57
Other Noncurrent Operating Liabilities	17	24	28	34
Commitments & Contingencies	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	339	465	493	249
Total Preferred & Common Equity	339	465	493	249
Preferred Stock	0.00	0.00	0.00	0.00
Total Common Equity	339	465	493	249
Common Stock	1,168	1,140	1,038	939
Retained Earnings	-830	-677	-559	-683
Accumulated Other Comprehensive Income / (Loss)	-6.95	-6.60	-6.66	-6.66
Other Equity Adjustments	8.19	9.35	20	0.00

This table presents Zymeworks' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric	Q1 2025	Q3 2024	Q2 2024	Q1 2024	Q3 2023	Q2 2023	Q1 2023
Period end date	3/31/2025	9/30/2024	6/30/2024	3/31/2024	9/30/2023	6/30/2023	3/31/2023
Total Assets	426	487	516	554	556	602	601
Total Current Assets	306	344	383	394	375	420	426
Cash & Equivalents	76	122	71	115	94	142	182
Short-Term Investments	189	175	259	230	201	198	159
Accounts Receivable	25	24	32	31	67	49	67
Prepaid Expenses	17	23	21	18	12	31	19
Plant, Property, & Equipment, net	17	18	18	19	21	22	24
Total Noncurrent Assets	102	125	114	141	161	159	151
Long-Term Investments	56	78	66	75	96	92	72
Goodwill	12	12	12	12	12	12	12
Intangible Assets	3.36	6.58	7.45	25	26	25	26
Noncurrent Deferred & Refundable Income Taxes	4.85	4.21	3.95	3.70	1.32	1.36	1.41
Other Noncurrent Operating Assets	26	25	24	25	26	29	39
Total Liabilities & Shareholders' Equity	426	487	516	554	556	602	601
Total Liabilities	101	120	109	116	132	153	127
Total Current Liabilities	65	84	55	57	73	94	67
Accounts Payable	38	52	44	47	68	70	59
Current Deferred Revenue	23	27	5.52	3.44	0.09	18	2.35
Current Deferred & Payable Income Tax Liabilities	0.13	2.07	1.93	1.86	0.83	1.16	0.84
Other Current Liabilities	3.26	2.94	2.84	4.16	4.13	4.71	4.88
Total Noncurrent Liabilities	35	36	55	59	59	60	60
Noncurrent Deferred Revenue	15	15	33	33	33	31	31
Noncurrent Deferred & Payable Income Tax Liabilities	4.82	3.46	3.40	3.35	1.97	1.92	1.86
Other Noncurrent Operating Liabilities	16	18	18	23	24	27	27
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	325	367	406	438	424	449	474
Total Preferred & Common Equity	325	367	406	438	424	449	474
Preferred Stock	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Common Equity	325	367	406	438	424	449	474
Common Stock	1,176	1,163	1,153	1,147	1,086	1,082	1,053
Retained Earnings	-853	-798	-747	-709	-663	-634	-583
Accumulated Other Comprehensive Income / (Loss)	-6.41	-6.00	-7.90	-7.72	-8.30	-7.81	-5.94
Other Equity Adjustments	8.18	8.19	8.19	8.19	9.35	9.35	9.43

This table displays calculated financial ratios and metrics derived from Zymeworks' official financial filings.

Metric	2024	2023	2022	2021	2020
Period end date	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020
Growth Metrics	-	-	-	-	-
Revenue Growth	0.38%	-81.57%	1,446.03%	-31.50%	0.00%
EBITDA Growth	-3.06%	-184.68%	170.16%	-16.63%	0.00%
EBIT Growth	1.72%	-205.55%	161.42%	-15.34%	0.00%
NOPAT Growth	0.68%	-180.52%	179.51%	-15.02%	0.00%
Net Income Growth	-3.39%	-195.44%	158.69%	-17.33%	0.00%
EPS Growth	5.81%	-190.53%	141.21%	-28.77%	0.00%
Operating Cash Flow Growth	6.98%	-182.09%	174.88%	-27.11%	0.00%
Free Cash Flow Firm Growth	3.19%	-190.99%	179.00%	0.00%	0.00%
Invested Capital Growth	70.36%	5,377.16%	96.32%	0.00%	0.00%
Revenue Q/Q Growth	22.68%	-83.53%	0.00%	0.00%	0.00%
EBITDA Q/Q Growth	2.12%	-155.22%	0.00%	0.00%	0.00%
EBIT Q/Q Growth	1.71%	-168.11%	0.00%	0.00%	0.00%
NOPAT Q/Q Growth	0.87%	-150.68%	0.00%	0.00%	0.00%
Net Income Q/Q Growth	-7.94%	-157.82%	0.00%	0.00%	0.00%
EPS Q/Q Growth	-9.46%	-153.09%	0.00%	0.00%	0.00%
Operating Cash Flow Q/Q Growth	-101.61%	-160.64%	0.00%	0.00%	0.00%
Free Cash Flow Firm Q/Q Growth	-83.22%	0.00%	0.00%	0.00%	0.00%
Invested Capital Q/Q Growth	284.61%	-74.30%	0.00%	0.00%	0.00%
Profitability Metrics	-	-	-	-	-
Gross Margin	100.00%	100.00%	100.00%	100.00%	100.00%
EBITDA Margin	-164.29%	-160.03%	34.82%	-767.40%	-450.67%
Operating Margin	-179.69%	-181.62%	31.64%	-808.22%	-481.29%
EBIT Margin	-178.96%	-182.80%	31.91%	-803.31%	-477.06%
Profit (Net Income) Margin	-160.80%	-156.13%	30.14%	-794.01%	-463.54%
Tax Burden Percent	105.22%	99.52%	91.95%	99.76%	100.24%
Interest Burden Percent	85.40%	85.82%	102.73%	99.08%	96.93%
Effective Tax Rate	0.00%	0.00%	8.05%	0.00%	0.00%
Return on Invested Capital (ROIC)	-830.50%	-2,304.45%	0.00%	0.00%	0.00%
ROIC Less NNEP Spread (ROIC-NNEP)	-823.66%	-2,299.81%	0.00%	0.00%	0.00%
Return on Net Nonoperating Assets (RNNOA)	799.97%	2,279.67%	0.00%	0.00%	0.00%
Return on Equity (ROE)	-30.54%	-24.78%	33.51%	-85.05%	0.00%
Cash Return on Invested Capital (CROIC)	-882.55%	-1,232.29%	0.00%	0.00%	0.00%
Operating Return on Assets (OROA)	-26.16%	-22.60%	25.37%	-55.08%	0.00%
Return on Assets (ROA)	-23.51%	-19.30%	23.96%	-54.44%	0.00%
Return on Common Equity (ROCE)	-30.54%	-24.78%	33.51%	-85.05%	0.00%
Return on Equity Simple (ROE_SIMPLE)	-36.22%	-25.53%	25.22%	-85.05%	0.00%
Net Operating Profit after Tax (NOPAT)	-96	-97	120	-151	-131
NOPAT Margin	-125.78%	-127.13%	29.10%	-565.75%	-336.90%
Net Nonoperating Expense Percent (NNEP)	-6.85%	-4.64%	1.16%	-48.05%	0.00%
Return On Investment Capital (ROIC_SIMPLE)	-28.33%	-20.79%	24.35%	-	-
Cost of Revenue to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%
SG&A Expenses to Revenue	80.61%	92.68%	17.78%	159.52%	141.76%
R&D to Revenue	176.43%	188.94%	50.57%	748.70%	439.53%
Operating Expenses to Revenue	279.69%	281.62%	68.36%	908.22%	581.29%
Earnings before Interest and Taxes (EBIT)	-137	-139	132	-214	-186
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-125	-122	144	-205	-176
Valuation Ratios	-	-	-	-	-
Price to Book Value (P/BV)	2.72	1.41	1.00	0.00	0.00
Price to Tangible Book Value (P/TBV)	2.86	1.53	1.09	0.00	0.00
Price to Revenue (P/Rev)	12.09	8.61	1.20	0.00	0.00
Price to Earnings (P/E)	0.00	0.00	3.98	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	25.11%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	41.06	23.19	0.00	0.00	0.00
Enterprise Value to Revenue (EV/Rev)	7.84	2.61	0.00	0.00	0.00
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.01	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.02	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.02	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.01	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.02	0.00	0.00
Leverage & Solvency	-	-	-	-	-
Debt to Equity	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to Equity	0.00	0.00	0.00	0.00	0.00
Financial Leverage	-0.97	-0.99	-1.01	-1.02	0.00
Leverage Ratio	1.30	1.28	1.40	1.56	0.00
Compound Leverage Factor	1.11	1.10	1.44	1.55	0.00
Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%
Short-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%
Long-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	100.00%	100.00%	100.00%	100.00%	0.00%
Debt to EBITDA	0.00	0.00	0.00	0.00	0.00
Net Debt to EBITDA	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to EBITDA	0.00	0.00	0.00	0.00	0.00
Debt to NOPAT	0.00	0.00	0.00	0.00	0.00
Net Debt to NOPAT	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to NOPAT	0.00	0.00	0.00	0.00	0.00
Altman Z-Score	1.68	1.83	2.84	0.00	0.00
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-
Current Ratio	3.40	7.41	5.70	4.01	0.00
Quick Ratio	3.19	7.06	5.50	3.73	0.00
Cash Flow Metrics	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	-102	-105	116	-147	0.00
Operating Cash Flow to CapEx	-5,527.07%	-4,781.85%	1,768.21%	-1,551.52%	-3,512.83%
Free Cash Flow to Firm to Interest Expense	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow to Interest Expense	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00
Efficiency Ratios	-	-	-	-	-
Asset Turnover	0.15	0.12	0.79	0.07	0.00
Accounts Receivable Turnover	2.03	2.88	16.83	1.71	0.00
Inventory Turnover	0.00	0.00	0.00	0.00	0.00
Fixed Asset Turnover	4.07	3.41	17.37	1.17	0.00
Accounts Payable Turnover	0.00	0.00	0.00	0.00	0.00
Days Sales Outstanding (DSO)	180.08	126.95	21.69	213.61	0.00
Days Inventory Outstanding (DIO)	0.00	0.00	0.00	0.00	0.00
Days Payable Outstanding (DPO)	0.00	0.00	0.00	0.00	0.00
Cash Conversion Cycle (CCC)	180.08	126.95	21.69	213.61	0.00
Capital & Investment Metrics	-	-	-	-	-
Invested Capital	15	8.55	-0.16	-4.40	0.00
Invested Capital Turnover	6.60	18.13	-180.83	-12.13	0.00
Increase / (Decrease) in Invested Capital	6.02	8.71	4.24	-4.40	0.00
Enterprise Value (EV)	598	198	2.03	0.00	0.00
Market Capitalization	922	655	495	0.00	0.00
Book Value per Share	$4.92	$6.64	$7.56	$4.83	$0.00
Tangible Book Value per Share	$4.68	$6.11	$6.97	$4.18	$0.00
Total Capital	339	465	493	249	0.00
Total Debt	0.00	0.00	0.00	0.00	0.00
Total Long-Term Debt	0.00	0.00	0.00	0.00	0.00
Net Debt	-324	-456	-493	-253	0.00
Capital Expenditures (CapEx)	1.99	2.47	8.15	12	4.31
Debt-free, Cash-free Net Working Capital (DFCFNWC)	-14	-17	-43	-36	0.00
Debt-free Net Working Capital (DFNWC)	212	357	449	216	0.00
Net Working Capital (NWC)	212	357	449	216	0.00
Net Nonoperating Expense (NNE)	27	22	-4.33	61	49
Net Nonoperating Obligations (NNO)	-324	-456	-493	-253	0.00
Total Depreciation and Amortization (D&A)	11	17	12	9.58	10
Debt-free, Cash-free Net Working Capital to Revenue	-17.85%	-22.58%	-10.46%	-135.84%	0.00%
Debt-free Net Working Capital to Revenue	278.04%	469.88%	108.87%	810.97%	0.00%
Net Working Capital to Revenue	278.04%	469.88%	108.87%	810.97%	0.00%
Earnings Adjustments	-	-	-	-	-
Adjusted Basic Earnings per Share	($1.62)	($1.72)	$1.91	$0.00	$0.00
Adjusted Weighted Average Basic Shares Outstanding	75.85M	68.86M	65.19M	0.00	0.00
Adjusted Diluted Earnings per Share	($1.62)	($1.72)	$1.90	$0.00	$0.00
Adjusted Weighted Average Diluted Shares Outstanding	75.88M	68.86M	65.25M	0.00	0.00
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	69.58M	70.57M	64.04M	0.00	0.00
Normalized Net Operating Profit after Tax (NOPAT)	-84	-97	120	-151	-131
Normalized NOPAT Margin	-109.92%	-127.13%	29.10%	-565.75%	-336.90%
Pre Tax Income Margin	-152.82%	-156.87%	32.79%	-795.95%	-462.43%
Debt Service Ratios	-	-	-	-	-
EBIT to Interest Expense	0.00	0.00	0.00	0.00	0.00
NOPAT to Interest Expense	0.00	0.00	0.00	0.00	0.00
EBIT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00
NOPAT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00
Payout Ratios	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	-24.49%	0.00%	0.00%	0.00%	0.00%

This table displays calculated financial ratios and metrics derived from Zymeworks' official financial filings.

Metric	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Period end date	3/31/2025	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022
Growth Metrics	-	-	-	-	-	-	-	-	-	-	-
Revenue Growth	170.29%	83.33%	-3.07%	174.82%	-71.81%	-95.79%	527.37%	28.67%	1,756.89%	0.00%	0.00%
EBITDA Growth	36.74%	13.02%	-21.80%	19.20%	-41.49%	-106.51%	44.32%	20.81%	63.25%	0.00%	0.00%
EBIT Growth	31.83%	9.81%	-5.54%	21.26%	-35.04%	-107.61%	33.46%	16.51%	61.96%	0.00%	0.00%
NOPAT Growth	32.24%	5.14%	-2.91%	20.75%	-38.57%	-105.32%	34.00%	17.79%	62.47%	0.00%	0.00%
Net Income Growth	28.49%	-62.31%	-4.05%	26.33%	-29.98%	-104.68%	40.04%	20.84%	66.47%	0.00%	0.00%
EPS Growth	28.57%	-77.78%	4.88%	35.53%	-13.51%	-103.77%	43.06%	21.65%	68.91%	0.00%	0.00%
Operating Cash Flow Growth	90.96%	-397.46%	86.23%	-290.53%	54.72%	-95.74%	41.56%	88.33%	-50.13%	0.00%	0.00%
Free Cash Flow Firm Growth	-123.18%	14.10%	130.44%	56.59%	120.54%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Invested Capital Growth	-80.83%	70.36%	-123.72%	-38.41%	-70.96%	5,377.16%	0.00%	0.00%	0.00%	0.00%	0.00%
Revenue Q/Q Growth	-12.64%	93.94%	-16.85%	91.85%	-40.74%	2.54%	135.73%	-80.32%	-91.16%	15,198.10%	-51.65%
EBITDA Q/Q Growth	-22.41%	42.72%	21.11%	-14.37%	-68.31%	19.79%	47.67%	-100.28%	-107.75%	785.82%	25.58%
EBIT Q/Q Growth	-16.87%	36.43%	19.55%	-14.06%	-54.61%	25.61%	39.98%	-95.63%	-108.71%	750.41%	24.69%
NOPAT Q/Q Growth	-15.29%	35.05%	20.24%	-13.45%	-61.40%	29.53%	38.58%	-98.36%	-106.19%	974.95%	23.49%
Net Income Q/Q Growth	3.70%	21.25%	20.79%	-19.06%	-118.57%	49.52%	43.92%	-110.04%	-107.87%	746.72%	25.96%
EPS Q/Q Growth	6.25%	17.95%	20.41%	-16.67%	-133.33%	56.10%	46.05%	-105.41%	-107.74%	763.89%	25.77%
Operating Cash Flow Q/Q Growth	91.79%	-606.28%	76.48%	33.66%	-369.95%	132.70%	-566.78%	92.31%	-125.41%	548.35%	-33.18%
Free Cash Flow Firm Q/Q Growth	82.48%	-225.32%	172.78%	-245.02%	165.52%	55.59%	-3.77%	31.37%	0.00%	0.00%	0.00%
Invested Capital Q/Q Growth	-76.96%	284.61%	-177.18%	-41.61%	110.13%	-74.30%	100.45%	-72.47%	37,305.56%	0.00%	0.00%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-	-
Gross Margin	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%
EBITDA Margin	-82.11%	-58.60%	-198.41%	-209.13%	-350.81%	-123.51%	-157.90%	-711.31%	-69.90%	79.76%	-1,779.06%
Operating Margin	-94.48%	-71.60%	-213.78%	-222.87%	-376.89%	-138.37%	-201.36%	-772.84%	-76.68%	79.35%	-1,914.03%
EBIT Margin	-94.30%	-70.49%	-215.06%	-222.27%	-373.86%	-143.29%	-197.52%	-775.82%	-78.05%	79.18%	-1,862.41%
Profit (Net Income) Margin	-83.50%	-75.75%	-186.56%	-195.84%	-315.58%	-85.56%	-173.80%	-730.53%	-68.45%	76.88%	-1,818.55%
Tax Burden Percent	102.24%	132.12%	100.76%	100.18%	100.24%	75.41%	104.03%	103.34%	106.05%	96.57%	99.94%
Interest Burden Percent	86.61%	81.34%	86.09%	87.95%	84.21%	79.18%	84.58%	91.12%	82.70%	100.54%	97.70%
Effective Tax Rate	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	3.43%	0.00%
Return on Invested Capital (ROIC)	-592.07%	-330.91%	-733.63%	-729.59%	-342.34%	-1,755.72%	-3,911.83%	-29,189.68%	-794.62%	0.00%	0.00%
ROIC Less NNEP Spread (ROIC-NNEP)	-590.80%	-328.87%	-732.08%	-727.74%	-341.10%	-1,756.12%	-3,909.05%	-29,183.54%	-792.08%	0.00%	0.00%
Return on Net Nonoperating Assets (RNNOA)	574.65%	319.41%	708.61%	704.92%	311.99%	1,740.74%	3,602.63%	28,104.72%	691.26%	0.00%	0.00%
Return on Equity (ROE)	-17.42%	-11.50%	-25.02%	-24.67%	-30.35%	-14.98%	-309.20%	-1,084.96%	-103.36%	33.51%	0.00%
Cash Return on Invested Capital (CROIC)	-702.66%	-882.55%	0.00%	-669.51%	-157.46%	-1,232.29%	0.00%	0.00%	0.00%	0.00%	0.00%
Operating Return on Assets (OROA)	-17.98%	-10.30%	-25.64%	-24.94%	-32.68%	-17.72%	-163.87%	-576.92%	-57.96%	62.94%	0.00%
Return on Assets (ROA)	-15.92%	-11.07%	-22.24%	-21.97%	-27.59%	-10.58%	-144.19%	-543.25%	-50.83%	61.11%	0.00%
Return on Common Equity (ROCE)	-17.42%	-11.50%	-25.02%	-24.67%	-30.35%	-14.98%	-309.20%	-1,084.96%	-103.36%	33.51%	0.00%
Return on Equity Simple (ROE_SIMPLE)	-34.98%	0.00%	-30.97%	-27.70%	-28.76%	0.00%	48.37%	41.45%	36.45%	0.00%	0.00%
Net Operating Profit after Tax (NOPAT)	-18	-16	-24	-30	-26	-16	-23	-38	-19	308	-35
NOPAT Margin	-66.13%	-50.12%	-149.65%	-156.01%	-263.82%	-96.86%	-140.95%	-540.99%	-53.68%	76.63%	-1,339.82%
Net Nonoperating Expense Percent (NNEP)	-1.27%	-2.04%	-1.54%	-1.85%	-1.25%	0.40%	-2.77%	-6.14%	-2.54%	0.20%	0.00%
Return On Investment Capital (ROIC_SIMPLE)	-5.52%	-4.59%	-	-	-	-3.53%	-	-	-	62.57%	-
Cost of Revenue to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
SG&A Expenses to Revenue	62.65%	52.16%	86.58%	81.48%	157.43%	87.58%	102.80%	310.03%	47.63%	7.49%	604.03%
R&D to Revenue	131.83%	63.73%	227.21%	241.39%	319.46%	150.80%	198.56%	562.81%	129.05%	13.16%	1,410.00%
Operating Expenses to Revenue	194.48%	171.60%	313.78%	322.87%	476.89%	238.37%	301.36%	872.84%	176.68%	20.65%	2,014.03%
Earnings before Interest and Taxes (EBIT)	-26	-22	-34	-43	-37	-24	-33	-54	-28	319	-49
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-22	-18	-32	-40	-35	-21	-26	-50	-25	321	-47
Valuation Ratios	-	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	2.31	2.72	2.15	1.32	1.51	1.41	0.94	1.21	1.20	1.00	0.00
Price to Tangible Book Value (P/TBV)	2.42	2.86	2.27	1.39	1.65	1.53	1.03	1.32	1.31	1.09	0.00
Price to Revenue (P/Rev)	8.03	12.09	12.71	8.55	13.13	8.61	0.87	1.22	1.28	1.20	0.00
Price to Earnings (P/E)	0.00	0.00	0.00	0.00	0.00	0.00	1.96	2.94	3.29	3.98	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	50.98%	33.98%	30.44%	25.11%	0.00%
Enterprise Value to Invested Capital (EV/IC)	127.73	41.06	0.00	13.71	13.84	23.19	0.25	6.75	2.59	0.00	0.00
Enterprise Value to Revenue (EV/Rev)	4.59	7.84	6.68	2.24	4.80	2.61	0.02	0.25	0.35	0.00	0.00
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00	0.00	0.00	0.00	0.04	0.56	0.84	0.01	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00	0.00	0.00	0.00	0.04	0.60	0.88	0.02	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00	0.00	0.00	0.00	0.04	0.64	0.95	0.02	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00	0.00	0.00	0.00	0.04	0.68	1.34	0.01	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to Equity	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Financial Leverage	-0.97	-0.97	-0.97	-0.97	-0.91	-0.99	-0.92	-0.96	-0.87	-1.00	0.00
Leverage Ratio	1.28	1.30	1.32	1.31	1.27	1.28	1.31	1.34	1.27	1.40	0.00
Compound Leverage Factor	1.11	1.06	1.14	1.15	1.07	1.02	1.11	1.22	1.05	1.41	0.00
Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Short-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Long-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	0.00%
Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Altman Z-Score	2.37	2.50	2.19	1.52	2.24	2.48	1.43	1.75	2.63	3.79	0.00
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-	-
Current Ratio	4.71	3.40	4.10	7.01	6.92	7.41	5.14	4.49	6.33	5.70	0.00
Quick Ratio	4.45	3.19	3.82	6.62	6.61	7.06	4.98	4.16	6.06	5.50	0.00
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	-3.78	-22	17	-24	16	-25	-57	-54	-79	0.00	0.00
Operating Cash Flow to CapEx	-21,293.75%	-13,219.11%	-653.73%	-4,214.17%	-20,361.62%	3,919.66%	-4,587.85%	-797.88%	-21,552.07%	94,068.97%	-7,442.92%
Free Cash Flow to Firm to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.19	0.15	0.12	0.11	0.09	0.12	0.83	0.74	0.74	0.79	0.00
Accounts Receivable Turnover	3.36	2.03	1.37	1.55	1.03	2.88	6.86	9.17	6.67	16.83	0.00
Inventory Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Fixed Asset Turnover	5.24	4.07	3.17	3.07	2.38	3.41	22.08	20.01	18.97	17.37	0.00
Accounts Payable Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Sales Outstanding (DSO)	108.55	180.08	266.94	235.46	353.92	126.95	53.20	39.80	54.75	21.69	0.00
Days Inventory Outstanding (DIO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Payable Outstanding (DPO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Cash Conversion Cycle (CCC)	108.55	180.08	266.94	235.46	353.92	126.95	53.20	39.80	54.75	21.69	0.00
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-	-
Invested Capital	3.36	15	-7.89	10	18	8.55	33	17	60	-0.16	0.00
Invested Capital Turnover	8.95	6.60	4.90	4.68	1.30	18.13	27.75	53.96	14.80	-2,546.19	0.00
Increase / (Decrease) in Invested Capital	-14	6.02	-41	-6.37	-43	8.71	33	17	60	0.00	0.00
Enterprise Value (EV)	429	598	416	140	242	198	8.32	112	156	2.03	0.00
Market Capitalization	750	922	791	536	663	655	399	544	569	495	0.00
Book Value per Share	$4.67	$4.92	$5.17	$5.74	$6.21	$6.64	$6.26	$7.00	$7.39	$7.56	$0.00
Tangible Book Value per Share	$4.45	$4.68	$4.90	$5.47	$5.68	$6.11	$5.70	$6.42	$6.81	$6.97	$0.00
Total Capital	325	339	367	406	438	465	424	449	474	493	0.00
Total Debt	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Long-Term Debt	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt	-322	-324	-375	-396	-420	-456	-391	-432	-413	-493	0.00
Capital Expenditures (CapEx)	0.02	0.31	0.90	0.59	0.19	0.36	0.93	0.80	0.39	0.35	0.98
Debt-free, Cash-free Net Working Capital (DFCFNWC)	-24	-14	-37	-1.36	-8.12	-17	6.38	-13	18	-43	0.00
Debt-free Net Working Capital (DFNWC)	241	212	260	329	337	357	302	327	359	449	0.00
Net Working Capital (NWC)	241	212	260	329	337	357	302	327	359	449	0.00
Net Nonoperating Expense (NNE)	4.71	7.95	5.91	7.67	5.19	-1.91	5.42	13	5.26	-1.01	13
Net Nonoperating Obligations (NNO)	-322	-324	-375	-396	-420	-456	-391	-432	-413	-493	0.00
Total Depreciation and Amortization (D&A)	3.31	3.69	2.66	2.53	2.31	3.35	6.54	4.52	2.90	2.31	2.19
Debt-free, Cash-free Net Working Capital to Revenue	-25.62%	-17.85%	-60.03%	-2.18%	-16.08%	-22.58%	1.38%	-2.97%	4.09%	-10.46%	0.00%
Debt-free Net Working Capital to Revenue	258.46%	278.04%	417.79%	524.33%	667.66%	469.88%	65.38%	72.99%	80.48%	108.87%	0.00%
Net Working Capital to Revenue	258.46%	278.04%	417.79%	524.33%	667.66%	469.88%	65.38%	72.99%	80.48%	108.87%	0.00%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	($0.30)	($0.32)	($0.39)	($0.49)	($0.42)	($0.19)	($0.41)	($0.76)	($0.36)	$4.78	$0.00
Adjusted Weighted Average Basic Shares Outstanding	75.17M	75.85M	76.13M	76.39M	76.21M	68.86M	70.58M	67.28M	66.74M	65.19M	0.00
Adjusted Diluted Earnings per Share	($0.30)	($0.32)	($0.39)	($0.49)	($0.42)	($0.18)	($0.41)	($0.76)	($0.37)	$4.78	$0.00
Adjusted Weighted Average Diluted Shares Outstanding	75.23M	75.88M	76.16M	76.40M	76.25M	68.86M	70.58M	67.28M	66.74M	65.25M	0.00
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	69.68M	69.58M	68.88M	71.05M	70.70M	70.57M	70.00M	67.83M	64.17M	64.04M	0.00
Normalized Net Operating Profit after Tax (NOPAT)	-18	-16	-24	-30	-26	-16	-23	-38	-19	308	-35
Normalized NOPAT Margin	-66.13%	-50.12%	-149.65%	-156.01%	-263.82%	-96.86%	-140.95%	-540.99%	-53.68%	76.63%	-1,339.82%
Pre Tax Income Margin	-81.67%	-57.33%	-185.15%	-195.49%	-314.84%	-113.46%	-167.07%	-706.91%	-64.54%	79.61%	-1,819.65%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
NOPAT to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
EBIT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
NOPAT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Payout Ratios	-	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	-24.49%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

Frequently Asked Questions About Zymeworks' Financials

When does Zymeworks's fiscal year end?

According to the most recent income statement we have on file, Zymeworks' financial year ends in December. Their financial year 2024 ended on December 31, 2024.

How has Zymeworks' net income changed over the last 4 years?

Zymeworks' net income appears to be on a downward trend, with a most recent value of -$122.70 million in 2024, falling from -$180.55 million in 2020. The previous period was -$118.67 million in 2023. See Zymeworks' forecast for analyst expectations on what’s next for the company.

What is Zymeworks's operating income?

Zymeworks's total operating income in 2024 was -$137.11 million, based on the following breakdown:

Total Gross Profit: $76.30 million
Total Operating Expenses: $213.41 million

How has Zymeworks revenue changed over the last 4 years?

Over the last 4 years, Zymeworks' total revenue changed from $38.95 million in 2020 to $76.30 million in 2024, a change of 95.9%.

How much debt does Zymeworks have?

Zymeworks' total liabilities were at $124.32 million at the end of 2024, a 7.1% increase from 2023, and a 11.2% decrease since 2021.

How much cash does Zymeworks have?

In the past 3 years, Zymeworks' cash and equivalents has ranged from $66.10 million in 2024 to $400.91 million in 2022, and is currently $66.10 million as of their latest financial filing in 2024.

How has Zymeworks' book value per share changed over the last 4 years?

Over the last 4 years, Zymeworks' book value per share changed from 0.00 in 2020 to 4.92 in 2024, a change of 491.8%.

Related Companies

This page (NYSE:ZYME) was last updated on 5/21/2025 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Zymeworks (ZYME) Financials

Frequently Asked Questions About Zymeworks' Financials

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Zymeworks (ZYME) Financials

Annual Income Statements for Zymeworks

Quarterly Income Statements for Zymeworks

Annual Cash Flow Statements for Zymeworks

Quarterly Cash Flow Statements for Zymeworks

Annual Balance Sheets for Zymeworks

Quarterly Balance Sheets for Zymeworks

Annual Metrics And Ratios for Zymeworks

Quarterly Metrics And Ratios for Zymeworks

Frequently Asked Questions About Zymeworks' Financials

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools